drugset
drugset / Trial / NCT04366323

Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19

NCT04366323 ↗

Phase 1/2 Completed 26 enrolled Andalusian Network for Design and Translation of Advanced Therapies
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia

Timeline

Start
2020-04-27
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS Cell therapy 80 cells Intravenous

Indications

COVID-19